It appears that adding veliparib to chemotherapy can extend progression-free survival (PFS) in patients suffering from triple negative breast cancer (TNBC) with a ‘BRCA-like’ phenotype. This conclusion follows results from the SWOG S1416 clinical trial, which was led by researchers at the SWOG Cancer Research Network.
The SWOG Cancer Research Network is funded by the National Cancer Institute (NCI), and the trial results were published in Lancet Oncology.
